Patient Adherence to Evidence-Based Pharmacotherapy in Systolic Heart Failure and the Transition of Follow-Up from Specialized Heart Failure Outpatient Clinics to Primary Care
Key result
Participation in specialized heart failure clinics was associated with high 3-year adherence to RAS inhibitors (90%) and beta-blockers (88%), which was maintained after referral to primary care.
Why the study?
Does management in specialized heart failure clinics and subsequent transition to primary care maintain long-term adherence to evidence-based pharmacotherapy in patients with systolic heart failure?
Population
8,792 patients with systolic heart failure attending specialized heart failure clinics in Denmark from 2002…
Design
Cohort
Follow-up
Up to 3 years during clinic management and 1 year after…
Authors
Discussion
Loading...
Member takes
Implication
Supports HFC follow-up to sustain high adherence in systolic HF; leaves open need for RCTs to confirm practice impact.
Study Design
Type
Cohort (n=8,792)
Multicenter
Yes
Structured PICO
Does management in specialized heart failure clinics and subsequent transition to primary care maintain long-term adherence to evidence-based pharmacotherapy in patients with systolic heart failure?
P
Population
8,792 patients with systolic heart failure (mean age 68 years, 28% female) attending specialized heart failure clinics in Denmark, followed for up to 3 years.
E
Exposure
Management in specialized heart failure clinics and subsequent transition to general practitioner for continued management.
O
Outcome
Long-term adherence to and dosages of evidence-based pharmacotherapy (RAS inhibitors, beta-blockers, spironolactone) during and after participation in specialized heart failure clinics.
Long-term adherence to evidence-based heart failure pharmacotherapy is highly maintained both during specialized clinic management and after transition back to primary care.
Cite This Study
Gjesing et al. (2013) conducted a cohort in systolic heart failure (n=8,792). Specialized heart failure outpatient clinics was evaluated on Long-term adherence to evidence-based pharmacotherapy. Participation in specialized heart failure clinics was associated with high 3-year adherence to RAS inhibitors (90%) and beta-blockers (88%), which was maintained after referral to primary care.